Mostrar registro simples

dc.contributor.authorNeves, Gilda Angelapt_BR
dc.contributor.authorRates, Stela Maris Kuzept_BR
dc.contributor.authorFraga, Carlos Alberto Manssourpt_BR
dc.contributor.authorBarreiro, Eliezer J.pt_BR
dc.date.accessioned2013-07-03T01:42:55Zpt_BR
dc.date.issued2004pt_BR
dc.identifier.issn0100-4042pt_BR
dc.identifier.urihttp://hdl.handle.net/10183/72989pt_BR
dc.description.abstractThe understanding of the scientific basis of the erectile function expanded rapidly the range of therapies for treating erectile dysfunction in recent years. This article reviews the role of dopamine on the erection mechanisms and its importance for new pro-erectile drug design. The ability of dopaminergic agents to elicit penile erection has been described since 1975 and successively confirmed by numerous studies. The development of apomorphine SL (dopaminergic non selective agonist) to enhance erectile function represents a new pharmacological approach to the management of erectile dysfunction using CNS drugs. The search for selective D4 dopaminergic agents is being explored by some research groups and pharmaceutical companies.en
dc.format.mimetypeapplication/pdf
dc.language.isoporpt_BR
dc.relation.ispartofQuímica nova. São Paulo. Vol. 27, n. 6 (2004), p. 949-957pt_BR
dc.rightsOpen Accessen
dc.subjectErectile dysfunctionen
dc.subjectDisfunção erétil : tratamentopt_BR
dc.subjectDopaminergic agentsen
dc.subjectAgentes dopaminérgicospt_BR
dc.subjectApomorphineen
dc.titleAgentes dopaminérgicos e o tratamento da disfunção erétilpt_BR
dc.title.alternativeDopaminergic agents and erectile dysfunction treatment en
dc.typeArtigo de periódicopt_BR
dc.identifier.nrb000608830pt_BR
dc.type.originNacionalpt_BR


Thumbnail
   

Este item está licenciado na Creative Commons License

Mostrar registro simples